SUPPLEMENT
Q2 2020 — Sales of Key Products/Franchises
Q2 2020PDF · 4 pages214 KB
REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS 2020 2019 Reported Operational (1) Currency 2020 2019 Reported Operational (1) Currency CONSUMER HEALTH SEGMENT (2,3) BABY CARE US 96 $ 99 -3.5% -3.5% - 188 $ 186 1.2% 1.2% - Intl 260 344 -24.3% -16.6% -7.7% 529 651 -18.7% -12.6% -6.1% WW 356 443 -19.7% -13.6% -6.1% 717 837 -14.3% -9.5% -4.8% ORAL CARE US 170 155 9.7% 9.7% - 346 306 12.9% 12.9% - Intl 227 234 -2.8% 4.0% -6.8% 446 450 -0.8% 4.6% -5.4% WW 397 389 2.2% 6.3% -4.1% 792 756 4.8% 8.0% -3.2% OTC US 627 484 29.6% 29.6% - 1,316 991 32.8% 32.8% - Intl 522 580 -10.1% -5.0% -5.1% 1,181 1,160 1.8% 6.0% -4.2% WW 1,149 1,064 7.9% 10.7% -2.8% 2,497 2,151 16.1% 18.3% -2.2% SKIN HEALTH / BEAUTY(4) US 536 663 -19.2% -19.2% - 1,195 1,251 -4.5% -4.5% - Intl 471 539 -12.5% -8.2% -4.3% 929 1,041 -10.7% -7.4% -3.3% WW 1,007 1,202 -16.2% -14.3% -1.9% 2,124 2,292 -7.3% -5.8% -1.5% WOMEN'S HEALTH US 3 3 -2.9% -2.9% - 7 6 14.3% 14.3% - Intl 199 250 -20.4% -12.0% -8.4% 427 472 -9.6% -2.1% -7.5% WW 202 253 -20.1% -11.8% -8.3% 434 478 -9.3% -1.9% -7.4% WOUND CARE / OTHER US 126 132 -4.7% -4.7% - 245 234 4.7% 4.7% - Intl 59 61 -2.4% 3.7% -6.1% 111 114 -1.9% 2.8% -4.7% WW 185 193 -4.0% -2.1% -1.9% 356 348 2.6% 4.1% -1.5% TOTAL CONSUMER HEALTH US 1,557 1,537 1.3% 1.3% - 3,297 2,975 10.8% 10.8% - Intl 1,739 2,007 -13.4% -7.4% -6.0% 3,624 3,887 -6.8% -1.9% -4.9% WW 3,296 $ 3,544 -7.0% -3.6% -3.4% 6,921 $ 6,862 0.9% 3.6% -2.7% See footnotes at end of schedule % Change % Change -- 1 of 4 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS PHARMACEUTICAL SEGMENT (2,5) 2020 2019 Reported Operational (1) Currency 2020 2019 Reported Operational (1) Currency IMMUNOLOGY US 2,362 $ 2,379 -0.7% -0.7% - 4,772 $ 4,542 5.1% 5.1% - Intl 1,161 1,087 6.8% 11.0% -4.2% 2,389 2,175 9.8% 13.7% -3.9% WW 3,523 3,466 1.6% 3.0% -1.4% 7,161 6,717 6.6% 7.9% -1.3% REMICADE US 593 801 -25.8% -25.8% - 1,218 1,575 -22.7% -22.7% - US Exports (6) 133 62 * * - 243 138 75.7% 75.7% - Intl 208 244 -14.5% -8.7% -5.8% 464 496 -6.4% -1.6% -4.8% WW 935 1,107 -15.5% -14.2% -1.3% 1,925 2,209 -12.9% -11.8% -1.1% SIMPONI / SIMPONI ARIA US 256 281 -8.7% -8.7% - 528 544 -2.9% -2.9% - Intl 289 282 2.6% 6.8% -4.2% 547 543 0.8% 4.8% -4.0% WW 546 563 -3.0% -0.9% -2.1% 1,075 1,087 -1.1% 1.0% -2.1% STELARA US 1,138 1,058 7.5% 7.5% - 2,355 1,940 21.4% 21.4% - Intl 558 499 11.9% 15.5% -3.6% 1,161 1,022 13.6% 16.9% -3.3% WW 1,697 1,558 8.9% 10.1% -1.2% 3,516 2,963 18.7% 19.8% -1.1% TREMFYA US 241 176 36.7% 36.7% - 428 344 24.4% 24.4% - Intl 101 59 71.0% 73.4% -2.4% 210 108 94.0% 97.1% -3.1% WW 342 235 45.4% 46.0% -0.6% 638 452 41.1% 41.8% -0.7% OTHER IMMUNOLOGY US - - - - - - - - - - Intl 3 3 11.8% 21.6% -9.8% 6 6 2.7% 8.4% -5.7% WW 3 3 11.8% 21.6% -9.8% 6 6 2.7% 8.4% -5.7% INFECTIOUS DISEASES US 416 387 7.4% 7.4% - 852 744 14.5% 14.5% - Intl 463 475 -2.5% 2.6% -5.1% 946 964 -1.8% 2.7% -4.5% WW 878 862 1.9% 4.7% -2.8% 1,798 1,708 5.3% 7.8% -2.5% EDURANT / rilpivirine US 10 12 -14.0% -14.0% - 22 24 -6.9% -6.9% - Intl 246 198 24.5% 27.7% -3.2% 458 397 15.4% 18.4% -3.0% WW 256 210 22.2% 25.2% -3.0% 480 421 14.1% 17.0% -2.9% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 379 344 10.5% 10.5% - 775 659 17.7% 17.7% - Intl 130 191 -32.0% -26.1% -5.9% 314 399 -21.4% -15.8% -5.6% WW 510 535 -4.7% -2.6% -2.1% 1,089 1,058 2.9% 5.0% -2.1% OTHER INFECTIOUS DISEASES US 25 31 -18.7% -18.7% - 54 61 -11.2% -11.2% - Intl 87 86 1.0% 8.7% -7.7% 174 168 3.8% 9.4% -5.6% WW 113 117 -4.2% 1.5% -5.7% 229 229 -0.2% 3.9% -4.1% % Change % Change -- 2 of 4 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS 2020 2019 Reported Operational (1) Currency 2020 2019 Reported Operational (1) Currency NEUROSCIENCE US 778 664 17.4% 17.4% - 1,526 1,387 10.1% 10.1% - Intl 809 875 -7.6% -4.1% -3.5% 1,719 1,780 -3.5% -0.5% -3.0% WW 1,587 1,538 3.2% 5.2% -2.0% 3,245 3,167 2.5% 4.1% -1.6% CONCERTA / Methylphenidate US 55 15 * * - 107 112 -4.2% -4.2% - Intl 94 123 -23.0% -20.2% -2.8% 212 239 -11.0% -8.6% -2.4% WW 149 137 8.7% 11.2% -2.5% 320 351 -8.9% -7.2% -1.7% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 576 506 13.8% 13.8% - 1,120 989 13.2% 13.2% - Intl 303 312 -2.8% 0.3% -3.1% 642 619 3.7% 6.7% -3.0% WW 879 818 7.5% 8.6% -1.1% 1,762 1,608 9.5% 10.7% -1.2% RISPERDAL CONSTA US 74 81 -9.3% -9.3% - 150 158 -4.9% -4.9% - Intl 79 101 -21.2% -18.1% -3.1% 173 203 -14.9% -11.9% -3.0% WW 153 182 -15.9% -14.2% -1.7% 323 361 -10.5% -8.9% -1.6% OTHER NEUROSCIENCE US 75 62 21.5% 21.5% - 150 128 16.8% 16.8% - Intl 331 340 -2.5% 1.7% -4.2% 691 719 -3.9% -0.8% -3.1% WW 406 401 1.2% 4.7% -3.5% 841 847 -0.7% 1.8% -2.5% ONCOLOGY US 1,181 1,013 16.6% 16.6% - 2,356 1,975 19.3% 19.3% - Intl 1,609 1,684 -4.4% -0.9% -3.5% 3,448 3,240 6.4% 9.9% -3.5% WW 2,791 2,697 3.5% 5.7% -2.2% 5,804 5,215 11.3% 13.5% -2.2% DARZALEX US 492 369 32.9% 32.9% - 955 721 32.3% 32.3% - Intl 409 405 1.2% 5.9% -4.7% 883 682 29.6% 34.7% -5.1% WW 901 774 16.3% 18.8% -2.5% 1,838 1,403 31.0% 33.5% -2.5% ERLEADA US 136 62 * * - 255 120 * * - Intl 33 7 * * * 57 10 * * * WW 170 69 * * * 313 130 * * * IMBRUVICA US 447 367 21.5% 21.5% - 879 716 22.6% 22.6% - Intl 502 463 8.3% 13.4% -5.1% 1,101 898 22.6% 27.4% -4.8% WW 949 831 14.1% 17.0% -2.9% 1,980 1,615 22.6% 25.3% -2.7% VELCADE US - - - - - - - - - - Intl 98 224 -56.1% -55.2% -0.9% 206 487 -57.7% -56.9% -0.8% WW 98 224 -56.1% -55.2% -0.9% 206 487 -57.7% -56.9% -0.8% ZYTIGA / abiraterone acetate US 87 198 -55.6% -55.6% - 226 383 -40.9% -40.9% - Intl 480 500 -3.9% -2.0% -1.9% 1,032 994 3.8% 6.1% -2.3% WW 568 698 -18.6% -17.2% -1.4% 1,258 1,377 -8.6% -7.0% -1.6% OTHER ONCOLOGY US 20 16 22.9% 22.9% - 42 34 21.4% 21.4% - Intl 87 85 2.2% 5.9% -3.7% 169 169 -0.3% 3.3% -3.6% WW 106 101 5.5% 8.6% -3.1% 210 203 3.4% 6.3% -2.9% PULMONARY HYPERTENSION US 545 439 24.2% 24.2% - 1,031 869 18.7% 18.7% - Intl 243 251 -3.3% -1.0% -2.3% 503 477 5.3% 7.9% -2.6% WW 789 690 14.2% 15.0% -0.8% 1,534 1,346 13.9% 14.9% -1.0% OPSUMIT US 256 203 26.1% 26.1% - 485 375 29.3% 29.3% - Intl 150 146 3.0% 5.7% -2.7% 310 279 11.2% 14.1% -2.9% WW 406 348 16.5% 17.6% -1.1% 795 654 21.6% 22.8% -1.2% UPTRAVI US 254 175 44.5% 44.5% - 466 351 32.6% 32.6% - Intl 28 28 4.0% 7.3% -3.3% 66 50 33.6% 37.6% -4.0% WW 282 203 39.0% 39.5% -0.5% 532 401 32.7% 33.2% -0.5% OTHER PULMONARY HYPERTENSION US 37 61 -40.2% -40.2% - 81 143 -43.5% -43.5% - Intl 64 78 -17.6% -16.4% -1.2% 126 149 -15.1% -13.7% -1.4% WW 101 140 -27.5% -26.9% -0.6% 207 292 -29.0% -28.3% -0.7% CARDIOVASCULAR / METABOLISM / OTHER US 837 902 -7.2% -7.2% - 1,643 1,849 -11.1% -11.1% - Intl 347 373 -7.0% -2.4% -4.6% 701 771 -9.1% -5.6% -3.5% WW 1,184 1,275 -7.1% -5.8% -1.3% 2,344 2,620 -10.5% -9.5% -1.0% XARELTO US 559 549 1.7% 1.7% - 1,086 1,091 -0.5% -0.5% - Intl - - - - - - - - - - WW 559 549 1.7% 1.7% - 1,086 1,091 -0.5% -0.5% - INVOKANA / INVOKAMET US 132 132 -0.8% -0.8% - 249 286 -13.0% -13.0% - Intl 47 43 9.1% 14.8% -5.7% 105 92 14.1% 18.1% -4.0% WW 179 177 1.6% 3.1% -1.5% 354 379 -6.4% -5.5% -0.9% PROCRIT / EPREX US 70 113 -38.3% -38.3% - 146 261 -44.1% -44.1% - Intl 66 70 -5.0% -2.3% -2.7% 145 148 -2.2% -0.1% -2.1% WW 136 183 -25.6% -24.6% -1.0% 291 409 -28.9% -28.2% -0.7% OTHER US 78 107 -27.7% -27.7% - 163 211 -22.9% -22.9% - Intl 234 260 -10.2% -5.3% -4.9% 451 531 -15.0% -11.3% -3.7% WW 312 368 -15.3% -11.8% -3.5% 614 742 -17.3% -14.6% -2.7% TOTAL PHARMACEUTICAL US 6,120 5,783 5.8% 5.8% - 12,181 11,365 7.2% 7.2% - Intl 4,632 4,746 -2.4% 1.4% -3.8% 9,705 9,408 3.2% 6.7% -3.5% WW 10,752 $ 10,529 2.1% 3.9% -1.8% 21,886 $ 20,773 5.4% 7.0% -1.6% See footnotes at end of schedule % Change % Change -- 3 of 4 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS MEDICAL DEVICES SEGMENT (2,5) 2020 2019 Reported Operational (1) Currency 2020 2019 Reported Operational (1) Currency INTERVENTIONAL SOLUTIONS US 255 366 -30.5% -30.5% - 620 709 -12.6% -12.6% - Intl 335 385 -12.8% -10.9% -1.9% 697 774 -9.9% -8.0% -1.9% WW 590 750 -21.5% -20.5% -1.0% 1,317 1,482 -11.2% -10.2% -1.0% ORTHOPAEDICS US 869 1,331 -34.7% -34.7% - 2,119 2,649 -20.0% -20.0% - Intl 583 894 -34.8% -32.6% -2.2% 1,371 1,779 -22.9% -20.6% -2.3% WW 1,451 2,224 -34.7% -33.9% -0.8% 3,489 4,428 -21.2% -20.3% -0.9% HIPS US 137 216 -36.5% -36.5% - 343 429 -20.1% -20.1% - Intl 88 147 -39.8% -37.3% -2.5% 220 295 -25.4% -22.8% -2.6% WW 226 364 -37.8% -36.8% -1.0% 563 725 -22.3% -21.2% -1.1% KNEES US 108 218 -50.5% -50.5% - 322 441 -27.1% -27.1% - Intl 66 153 -56.8% -55.3% -1.5% 196 299 -34.6% -32.7% -1.9% WW 174 372 -53.1% -52.5% -0.6% 517 741 -30.1% -29.3% -0.8% TRAUMA US 354 407 -12.9% -12.9% - 761 824 -7.6% -7.6% - Intl 198 265 -25.2% -22.6% -2.6% 445 533 -16.5% -13.9% -2.6% WW 553 672 -17.8% -16.7% -1.1% 1,207 1,357 -11.1% -10.0% -1.1% SPINE, SPORTS & OTHER (7) US 270 490 -45.0% -45.0% - 693 955 -27.4% -27.4% - Intl 230 328 -29.9% -27.9% -2.0% 510 651 -21.7% -19.6% -2.1% WW 499 818 -39.0% -38.2% -0.8% 1,202 1,606 -25.1% -24.3% -0.8% SURGERY US 490 926 -47.0% -47.0% - 1,334 1,927 -30.8% -30.8% - Intl 1,060 1,427 -25.7% -22.6% -3.1% 2,317 2,821 -17.9% -14.8% -3.1% WW 1,551 2,353 -34.1% -32.2% -1.9% 3,651 4,748 -23.1% -21.3% -1.8% ADVANCED US 277 396 -30.0% -30.0% - 658 800 -17.7% -17.7% - Intl 498 633 -21.2% -18.4% -2.8% 1,065 1,209 -11.9% -8.9% -3.0% WW 775 1,029 -24.6% -22.9% -1.7% 1,723 2,009 -14.2% -12.4% -1.8% GENERAL US 213 530 -59.8% -59.8% - 676 1,127 -40.0% -40.0% - Intl 562 794 -29.2% -26.0% -3.2% 1,252 1,612 -22.4% -19.2% -3.2% WW 775 1,325 -41.5% -39.5% -2.0% 1,928 2,739 -29.6% -27.8% -1.8% VISION US 248 461 -46.1% -46.1% - 687 907 -24.2% -24.2% - Intl 447 701 -36.1% -34.8% -1.3% 1,075 1,383 -22.3% -20.8% -1.5% WW 695 1,161 -40.1% -39.3% -0.8% 1,762 2,290 -23.0% -22.2% -0.8% CONTACT LENSES / OTHER US 203 333 -39.0% -39.0% - 549 654 -16.1% -16.1% - Intl 352 509 -30.9% -29.6% -1.3% 819 1,011 -19.0% -17.6% -1.4% WW 554 842 -34.1% -33.3% -0.8% 1,368 1,666 -17.9% -17.0% -0.9% SURGICAL US 45 128 -64.6% -64.6% - 138 253 -45.3% -45.3% - Intl 96 191 -49.9% -48.8% -1.1% 256 371 -31.0% -29.6% -1.4% WW 141 319 -55.8% -55.2% -0.6% 394 624 -36.8% -36.0% -0.8% TOTAL MEDICAL DEVICES US 1,862 3,083 -39.6% -39.6% - 4,760 6,192 -23.1% -23.1% - Intl 2,426 3,406 -28.8% -26.4% -2.4% 5,460 6,756 -19.2% -16.8% -2.4% WW 4,288 $ 6,489 -33.9% -32.7% -1.2% 10,220 $ 12,948 -21.1% -19.8% -1.3% * Percentage greater than 100% or not meaningful (6) Reported as U.S. sales (1) Operational growth excludes the effect of translational currency (7) Previously referred to as Spine & Other (2) Unaudited (3) Previously referred to as Consumer (4) Previously referred to as Beauty (5) Certain prior year amounts have been reclassified to conform to current year product disclosures Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. % Change % Change -- 4 of 4 --